Cypherpunk Technologies (CYPH)
Builds a Zcash treasury and privacy technologies while retaining an oncology subsidiary.
$1.71
Pre-market+0.03 (+1.86%)
At close$1.68(−2.05%)
Leap Therapeutics Announces Publication of DeFianCe Study Results in Clinical Cancer Research
Peer-reviewed analyses establish baseline plasma DKK1 as a continuous quantitative biomarker predicting deepening sirexatamab benefit in 2L mCRC patients In DKK1-high 2L mCRC patients, sirexatamab improved response, progression-free survival, and overall survival when added to bevacizumab and chemotherapy CAMBRIDGE, Mass., Aug. 12, 2026 /PRNewswire/ -- Leap Therapeutics, Inc., the biotechnology subsidiary of Cypherpunk Technologies Inc. (Nasdaq: CYPH), today announced the publication of results from the randomized Phase 2 DeFianCe study of sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in Clinical Cancer Research.
